04:24
CICC Raises Fosun Pharma's Target Price to 61.98 Hong Kong Dollars, Expects Significant Potential in Innovative Drug Research
Jin10 data news on June 25th, CICC research report pointed out that Fuhong Hanlin (02696.HK) has the ability to transform from a profitable biosimilar company to a leading enterprise in the field of biologics. Including HLX43, HLX22, Serplulimab, and other innovative drugs under research have shown good clinical data performance, believed to have huge potential. Therefore, the target price has been raised from 20.33 Hong Kong dollars to 61.98 Hong Kong dollars, maintaining a buy rating. CICC believes that Fuhong Hanlin is actively expanding its global biosimilar business through cooperation with pharmaceutical companies. Its Han Quyou (trastuzumab) and Serplulimab have shown strong commercial performance, while the listing license applications for HLX14 and HLX11 are currently under FDA review, and it is believed that they can open up overseas sources of income.

